Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 78
- 试验地点
- 5
- 主要终点
- The adverse events associated with one or multiple CAR T-cell product infusions will be assessed
研究概览
简要总结
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express two chimeric antigen receptors (CARs). One is to recognize CD19 and the other is to recognize CD22, both of which are proteins expressed on the surface of the leukemic cell in patients with CD19+CD22+ leukemia. The CAR enables the T-cell to recognize and kill the leukemic cell through recognition of CD19 and CD22. This is a phase 1 study designed to determine the safety of the CAR+ T-cells and the feasibility of making enough to treat patients with CD19+CD22+ leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •First 2 subjects: male and female subjects age ≥18 and < 27 years (as of 2/16/18 the first 2 subjects were enrolled and treated); subsequent subjects <31 years.
- •Diagnosis of CD19+22+ leukemia
- •Disease status:
- •If post allogeneic HCT: Confirmed CD19+CD22+ leukemia recurrence defined as at least 0.01% disease following allogeneic HCT
- •If relapse/refractory status with no prior history of allogeneic HCT, one of the following:
- •Second or greater marrow relapse, with or without extramedullary disease
- •First marrow relapse at end of first month or re-induction with marrow having at least 0.01 % blasts by morphology and/or MPF
- •Primary refractory as defined as greater than 5% blasts by multi-parameter flow after at least 2 separate induction regimens.
- •Subject has indication for HCT but has been deemed ineligible, inclusive of persistent MRD prior to HCT
- •Asymptomatic from CNS involvement, if present, and in the opinion of the Principal Investigator with a reasonable expectation that disease burden can be controlled in the interval between enrollment and T-cell infusion. Subjects with significant neurologic deterioration will not be eligible for T-cell infusion until stabilized.
- •Free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollment
- •Lansky or Karnofsky performance score of at least 50
- •Life expectancy of at least 8 weeks
- •Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy
- •At least 7 days post last chemotherapy administration (excluding intrathecal maintenance chemotherapy)
- •At least 7 das post last systemic corticosteroids administration (unless physiologic replacement dosing)
- •No prior genetically modified cell therapy that is still detectable or virotherapy
- •Adequate organ function
- •Adequate laboratory values
- •Willing to participate in long-term follow-up for up to 15 years, if enrolled in the study and receive T cell infusion
- •Patients of childbearing/fathering potential must agree to use highly effective contraception from the time of initial T cell infusion through 12 months following the last T cell infusion
排除标准
- •Presence of active clinically significant CNS dysfunction
- •Pregnant or breast-feeding
- •Unable to tolerate apheresis procedure
- •Presence of active malignancy other than CD19+CD22+ leukemia
- •Presence of active severe infection
- •Presence of any concurrent medical condition that, in the opinion of the Principal Investigator, would prevent the patient from undergoing protocol-specified therapy
研究组 & 干预措施
Patient-derived CD19- and CD22 specific CAR v1
Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
干预措施: Patient-derived CD19- and CD22 specific CAR (Biological)
Patient-derived CD19- and CD22 specific CAR v2
Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
干预措施: Patient-derived CD19- and CD22 specific CAR (Biological)
结局指标
主要结局
The adverse events associated with one or multiple CAR T-cell product infusions will be assessed
时间窗: 30 days
Type, frequency, severity, and duration of adverse events will be summarized
The number of successfully and unsuccessfully manufactured and infused CAR T-cell products will be assessed
时间窗: 28 days
Proportion of products successfully manufactured and infused
次要结局
未报告次要终点
研究者
Colleen Annesley
Medical Director, Seattle Children's Therapeutics
Seattle Children's Hospital